Pharmacokinetics of propofol and its conjugates after continuous infusion in normal and in renal failure patients: a preliminary study. 1993

N Nathan, and J Debord, and F Narcisse, and J L Dupuis, and M Lagarde, and D Benevent, and G Lachatre, and P Feiss
Department of Pharmacology and Toxicology, CHU Dupuytren, Limoges, France.

The pharmacokinetics of propofol, 2,6 diisopropylphenol, were compared in 6 end-stage renal failure patients aged 66.3 +/- 12.1 years and in 5 normal patients aged 45.5 +/- 13.5 years. Anesthesia was induced with propofol (2 and 2.5 mg.kg-1 respectively) and fentanyl (0.1 mg). Anesthesia was maintained with propofol (9 and 10 mg.kg-1 x h-1 respectively). Patients breathed spontaneously a 50 per cent oxygen in nitrous oxide mixture. Two ml blood samples were taken during anesthesia and at regular intervals until up to 24 hours after infusion. Plasma levels of propofol were determined by HPLC with electrochemical detection. Propofol conjugates were determined after hydrolysis with beta glucuronidase or HCl. Results were expressed as median [lower-upper percentiles]. Propofol clearance (1.53 [1.02-2.10] L.min-1 x kg-1 versus 1.65 [1.39-1.78] L.min-1 x kg-1 in normal patients), and half-lives elimination were not modified by renal failure. Renal failure patients exhibited a higher volume of distribution at steady state as compared to normal patients (19.28 [11.71-76.81] L.kg-1 versus 8.60 [6.58-9.81] L.kg-1, p < 0.05). Renal failure did not affect the production of conjugates but they accumulated in blood of renal failure patients. Despite this, no difference in time to eyes opening and propofol concentration were observed, confirming the absence of clinical effect of these metabolites.

UI MeSH Term Description Entries
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D005260 Female Females
D005966 Glucuronidase Endo-beta-D-Glucuronidase,Endoglucuronidase,Exo-beta-D-Glucuronidase,beta-Glucuronidase,Endo beta D Glucuronidase,Exo beta D Glucuronidase,beta Glucuronidase
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006868 Hydrolysis The process of cleaving a chemical compound by the addition of a molecule of water.
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

N Nathan, and J Debord, and F Narcisse, and J L Dupuis, and M Lagarde, and D Benevent, and G Lachatre, and P Feiss
March 1988, Anaesthesia,
N Nathan, and J Debord, and F Narcisse, and J L Dupuis, and M Lagarde, and D Benevent, and G Lachatre, and P Feiss
January 1985, Postgraduate medical journal,
N Nathan, and J Debord, and F Narcisse, and J L Dupuis, and M Lagarde, and D Benevent, and G Lachatre, and P Feiss
January 1987, Annales francaises d'anesthesie et de reanimation,
N Nathan, and J Debord, and F Narcisse, and J L Dupuis, and M Lagarde, and D Benevent, and G Lachatre, and P Feiss
February 2001, British journal of anaesthesia,
N Nathan, and J Debord, and F Narcisse, and J L Dupuis, and M Lagarde, and D Benevent, and G Lachatre, and P Feiss
October 2002, International journal of clinical pharmacology and therapeutics,
N Nathan, and J Debord, and F Narcisse, and J L Dupuis, and M Lagarde, and D Benevent, and G Lachatre, and P Feiss
May 1992, British journal of anaesthesia,
N Nathan, and J Debord, and F Narcisse, and J L Dupuis, and M Lagarde, and D Benevent, and G Lachatre, and P Feiss
April 2004, British journal of clinical pharmacology,
N Nathan, and J Debord, and F Narcisse, and J L Dupuis, and M Lagarde, and D Benevent, and G Lachatre, and P Feiss
January 1989, Acta anaesthesiologica Belgica,
N Nathan, and J Debord, and F Narcisse, and J L Dupuis, and M Lagarde, and D Benevent, and G Lachatre, and P Feiss
January 1987, Dermatologica,
N Nathan, and J Debord, and F Narcisse, and J L Dupuis, and M Lagarde, and D Benevent, and G Lachatre, and P Feiss
January 1990, Acta anaesthesiologica Belgica,
Copied contents to your clipboard!